Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT01895972 Completed - Glaucoma Clinical Trials

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

JUPITER
Start date: July 5, 2013
Phase: Phase 3
Study type: Interventional

The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.

NCT ID: NCT01881126 Completed - Glaucoma Clinical Trials

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Start date: June 2013
Phase: Phase 4
Study type: Interventional

This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

NCT ID: NCT01868126 Completed - Clinical trials for Open-angle Glaucoma or Ocular Hypertension

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and efficacy of four concentrations of DE-117 ophthalmic solution.

NCT ID: NCT01864642 Completed - Glaucoma Clinical Trials

Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects

OMT4OHT
Start date: July 2013
Phase: N/A
Study type: Interventional

The hypothesis is that osteopathic manipulative treatment (OMT)will significantly reduce intraocular pressure (IOP) in individuals with ocular hypertension (OHT) and glaucoma suspect patients.

NCT ID: NCT01863953 Completed - Glaucoma Clinical Trials

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

Start date: June 2013
Phase: Phase 2
Study type: Interventional

This is a safety and efficacy study of fixed-combination bimatoprost and brimonidine compared with LUMIGAN® and ALPHAGAN® in patients with chronic glaucoma or ocular hypertension.

NCT ID: NCT01853085 Completed - Ocular Hypertension Clinical Trials

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Start date: April 1, 2013
Phase:
Study type: Observational

The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice. All treatment decisions lie with the physician.

NCT ID: NCT01833741 Completed - Ocular Hypertension Clinical Trials

A Study of LUMIGAN® RC in the Clinical Setting

Start date: December 2009
Phase: Phase 4
Study type: Interventional

This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

NCT ID: NCT01830140 Completed - Glaucoma Clinical Trials

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Start date: July 2013
Phase: Phase 3
Study type: Interventional

This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).

NCT ID: NCT01814761 Completed - Ocular Hypertension Clinical Trials

A Study of Bimatoprost 0.01% in the Clinical Setting

APPEAL-Taiwan
Start date: May 2013
Phase: Phase 4
Study type: Observational

This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).

NCT ID: NCT01789736 Completed - Ocular Hypertension Clinical Trials

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

Start date: February 2013
Phase: Phase 2
Study type: Interventional

In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.